Available Until 8/23/2026

Pediatrics Certificate

Release DateAugust 23, 2023
Expiration DateAugust 23, 2026

ACPE Numbers: Various – see below
Activity Type: Application-based
CE Contact Hour(s):  up to 27.5 contact hours


The Pediatrics Certificate is self-guided, with online learning activities that are intended for pharmacists and designed to provide focused education on pediatrics, beginning with the unique approach to caring for and assessing a pediatric patient, then progressing to greater depth into the most commonly treated pediatric conditions and disorders seen in acute care and outpatient settings. Upon completion of all the modules, learners should be proficient in caring for a pediatric patient. 

Treatment information accurate as of August 23, 2023.

Professional Certificate Requirement

Once a learner has completed the educational curriculum, they will have the opportunity to complete an online comprehensive exam. Once the learner completes the exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the professional certificate.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity is intended for pharmacists responsible for the care of pediatric patients, or who have an interest in learning more about pediatric pharmacy practice.

Learning Activity

ACPE Number

Contact Hours

Introduction to Pediatrics 



Medication Safety



Fluids, Electrolytes, and Nutrition



Neonatology and Extracorporeal Membrane Oxygenation



Pain and Sedation



Cardiac and Pulmonary Diseases



Infectious Diseases



Neurological / Psychiatric, Gastrointestinal, and Endocrine Disorders



Pharmacogenomics, Hematology and Oncology Conditions, and Toxicology



  →  Final Assessment:(80%passing score required)

Introduction to Pediatrics
ACPE #: 0204-0000-23-803-H01-P

Learning Objectives:
• Compare and contrast an assessment of a pediatric patient to an adult patient.
• Design a communication plan for a pediatric patient.
• Recognize normal growth, lab values, and vital signs for a pediatric patient.
• Apply principles of pharmacokinetic changes during growth while assessing medication orders for pediatric patients.
• Calculate creatinine clearance for a pediatric patient.
• Use resources for answering medication questions related to pediatrics, pregnancy, and lactation.
• Calculate and double check a weight-based or body surface area-based dose for a pediatric patient.
• Identify common dosage formulation issues for pediatric patients.
• Discuss pediatric specific concepts and challenges related to sterile and non-sterile compounding.
• Identify appropriate devices and techniques to ensure safe medication administration and adherence in pediatric patients.

Medication Safety
ACPE #: 0204-0000-23-804-H05-P

Learning Objectives:
• Differentiate risk factors that lead to adverse drug events in pediatric patients.
• Apply risk mitigation strategies to improve patient safety in pediatric patients.
• Identify methods to optimize healthcare technology for safe care of pediatric patients.

Fluids, Electrolytes, and Nutrition
ACPE #: 0204-0000-23-805-H01-P

Learning Objectives:
• Describe pediatric intravenous fluids appropriate for a pediatric patient.
• Recognize the signs and symptoms of pediatric dehydration.
• Differentiate characteristics of various peripheral and central venous access devices.
• Compute a pediatric patient’s maintenance intravenous fluid rate and potential fluid deficit.
• Design a fluid replacement regimen for a pediatric dehydration patient.
• Explain why neonates and infants require a specialized amino acid solution when receiving parenteral nutrition.
• Discuss complications and limitations patients may experience with parenteral nutrition.
• Identify monitoring parameters for a pediatric patient receiving parenteral nutrition.
• Recommend an appropriate feeding route and regimen.
• Explain how to administer medications to a patient with an enteral feeding tube.

Neonatology and Extracorporeal Membrane Oxygenation
ACPE #: 0204-0000-23-806-H01-P

Learning Objectives:
• Summarize physiologic differences in newborns including pharmacokinetic and pharmacodynamic differences.
• Identify standard interventions recommended/required at birth along with the rationale for each.
• Apply strategies utilized in prevention of bronchopulmonary dysplasia.
• Compare treatment options for each of the following: apnea of prematurity, necrotizing enterocolitis, respiratory distress of the newborn, and patent ductus arteriosus.
• Describe unexpected complications encountered in newborns.
• Develop pharmacotherapy recommendations for the management of complications in the newborn.
• Summarize pharmacokinetic and pharmacodynamic changes that occur during extracorporeal membrane oxygenation.

Pain and Sedation
ACPE #: 0204-0000-23-807-H08-P

Learning Objectives:
• Select the most appropriate scale to assess pain and sedation when given a neonatal patient case.
• Recommend the most appropriate intervention/agent according to the six-step approach to analgesia in the neonatal patient when given a patient case.
• Compare and contrast the short- and long-term effects in preterm neonates with the use of morphine, fentanyl, dexmedetomidine, and midazolam for sedation during mechanical ventilation.
• Compare and contrast scales used to assess pain and sedation in critically ill infants and children.
• Select a first-line opioid infusion (i.e., morphine, hydromorphone, fentanyl, remifentanil) for a critically ill child when given a patient case.
• Identify the advantages and disadvantages of the use of midazolam, dexmedetomidine, and ketamine as a first-line sedative infusion when given a patient case.

Cardiac and Pulmonary Diseases
ACPE #: 0204-0000-23-808-H01-P

Learning Objectives:
• Describe the pathophysiology of congenital heart diseases and pulmonary hypertension.
• Identify pharmacokinetic and pharmacodynamic facets of medications used to treat congenital heart diseases and pulmonary hypertension.
• Explain place-in-therapy of medications used to treat congenital heart diseases and pulmonary hypertension.
• Differentiate place-in-therapy of presented medications for patients with congenital heart diseases and pulmonary hypertension.
• Identify the clinical criteria necessary for the diagnosis of Kawasaki Disease.
• Determine the appropriate therapeutic interventions based on patient-specific presentation.
• Describe the structured approach for the assessment and treatment of pediatric patients requiring advanced life support.
• Identify the appropriate therapeutic interventions based on patient-specific presentation.
• Provide recommendations for the diagnosis, evaluation, and treatment of hypertension in a pediatric patient.
• List medications used to treat common chronic complications of cystic fibrosis.
• Develop an antibiotic plan for treatment of a cystic fibrosis pulmonary exacerbation in an outpatient and inpatient setting.
• Apply the stepwise approach for chronic asthma management to a patient case.
• Design an acute treatment regimen for an asthma exacerbation.
• Identify cough and cold medications that should be avoided in pediatric patients.

Infectious Diseases
ACPE #: 0204-0000-23-809-H01-P

Learning Objectives:
• Analyze the impact of components that comprise an antimicrobial stewardship program.
• Develop an immunization care plan for a hospitalized neonate, child, and adolescent.
• Justify empiric antimicrobial treatment recommendations for sepsis and urinary tract infections.
• Discuss issues in treating pediatric patients presenting with COVID-19.
• Differentiate risk factors, common etiologies, and the clinical presentation of a pediatric patient with acute otitis media, bronchiolitis, pneumonia, or meningitis.
• Develop a treatment plan for a pediatric patient with acute otitis media, bronchiolitis, influenza, pneumonia, or meningitis.
• Develop an appropriate antimicrobial therapy regimen for common skin / soft tissue and/or bone / joint infections when given a pediatric patient case.
• Compare recommended antimicrobial regimens for Clostridium difficile infections in pediatric patients to adult patients using the 2017 Clinical Practice Guidelines for Clostridium difficile infection in adults and children.
• Develop an antifungal treatment regimen in a critically ill pediatric patient with candidemia.

Neurological / Psychiatric, Gastrointestinal, and Endocrine Disorders
ACPE #: 0204-0000-23-810-H01-P

Learning Objectives:
• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients, including common epilepsy syndromes.
• Identify first-line medications for the treatment of acute neurologic conditions in children, including status epilepticus.
• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients, including migraine headaches.
• Identify first-line medications for the treatment of acute neurologic conditions in children, including migraine headaches.
• Compare drug therapies used for the treatment of common neurologic conditions in pediatric patients including cerebral palsy.
• Recommend pharmacotherapy regimens with good patient tolerability to manage symptoms in children with attention-deficit hyperactivity disorder or autism spectrum disorder.
• Apply recommendations for the safe and effective use of antidepressants to manage depression, anxiety and PTSD symptoms in children and adolescents.
• Compare the strength of evidence and tolerability of antipsychotics and mood stabilizers for managing bipolar disorder and schizophrenia in children and adolescents.
• Design a treatment regimen for an infant presenting with GERD.
• Calculate the replacement fluid needs for a pediatric patient with acute diarrhea.
• Create a treatment plan for a pediatric patient with functional constipation.
• Design a monitoring plan for agents used in ulcerative colitis and Crohn’s disease in pediatric patients.
• Develop a treatment plan for a child with type 1 or type 2 diabetes mellitus.
• Select appropriate devices for treating and monitoring a child with type 1 diabetes mellitus.

Pharmacogenomics, Hematology and Oncology Conditions, and Toxicology
ACPE #: 0204-0000-23-811-H01-P

Learning Objectives:

• Describe pediatric-specific principles of pharmacogenomics.
• List currently available clinical pharmacogenomics guidelines that have implications for pediatrics.
• Apply available clinical guidelines to a sample patient case.
• Evaluate chemotherapy regimens used commonly in pediatric oncology for indication, dosing, common toxicities, supportive care and monitoring parameters.
• Describe the clinical presentation, pharmacotherapeutic plan and common toxicities of a pediatric patient with acute lymphoblastic leukemia.
• Design a maintenance chemotherapy treatment plan for a pediatric patient with acute lymphoblastic leukemia based on pharmacogenomic patient data.
• Apply evidence-based recommendations in the management of patients with sickle cell disease.
• Identify novel therapeutic treatment strategies for patients with sickle cell disease.
• Analyze anticoagulation treatment strategies in the management of pediatric venous thromboembolism.
• Recognize common toxidromes and antidotes.
• Develop treatment regimens for poisonings.

Kelly S. Bobo, PharmD, MBA, BCPS, BCPPS
Clinical Pharmacy Manager
Le Bonheur Children’s Hospital
Assistant Professor
University of Tennessee Health Science Center
Memphis, Tennessee

M. Petrea Cober, PharmD, BCNSP, BCPPS, FASPEN
Clinical Pharmacy Specialist – Neonatal Intensive Care Unit
Akron Children’s Hospital
Professor of Pharmacy Practice, Director of Professional Development
Northeast Ohio Medical University
Akron, Ohio

Hailey Collier, PharmD, BS, RPh, BCPPS
Clinical Pharmacy Specialist
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Justin W. Cole, PharmD, BCPS
Chair of Pharmacy Practice
Associate Professor of Pharmacy Practice
Cedarville University School of Pharmacy
Cedarville, Ohio

Michelle Condren, PharmD, BCPPS, CDCES, AE-C, FPPA
Professor and Vice Chair for Research
University of Oklahoma School of Community Medicine
Tulsa, Oklahoma

Julie A. Dopheide, PharmD, BCPP, FASHP
Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences
University of Southern California School of Pharmacy and Keck School of Medicine
Los Angeles, California

Joshua Elder, PharmD, BCPS, BCOP
Clinical Specialist - Pediatric Hematology, Oncology, and Stem Cell Transplant
Director, PGY2 Oncology Pharmacy Residency
Norton Children’s Hospital
Louisville, Kentucky

Lea S. Eiland, PharmD, BCPPS, BCPS, FASHP, FPPA
Clinical Professor and Associate Department Head of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Auburn, Alabama

Alexandra R. Funk, PharmD, DABAT
Clinical Toxicologist and Director
Central Ohio Poison Center
Nationwide Children’s Hospital
Columbus, Ohio

Manager, Pharmacy Clinical Research Programs
Clinical Pharmacist, Division of Gastroenterology, Hepatology and Nutrition
Boston Children’s Hospital
Assistant Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Amy P. Holmes, PharmD, BCPPS
Neonatal Intensive Care Unit Pharmacist
Brenner Children’s Hospital
Wake Forest Baptist Medical Center
Winston Salem, North Carolina

Hyun Kim, PharmD
Clinical Pharmacist, Department of Pharmacy
Boston Children’s Hospital
Adjunct Faculty, School of Pharmacy
MCPHS University - Boston
Boston, Massachusetts

Peter N. Johnson, PharmD, BCPS, BCPPS, FPPA, FCCM
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Katherine I. Lemming, PharmD
Clinical Pharmacy Specialist, Pediatric Cardiology – Cardiac Intensive Care
Department of Pharmacy
Texas Children's Hospital
Houston, Texas

Sherry Luedtke, PharmD, FPPA
Associate Professor, Pharmacy Practice
Jerry H. Hodge School of Pharmacy
Texas Tech University Health Science Center
Amarillo, Texas

Rachel Meyers, PharmD, BCPS, BCPPS, FPPA
Clinical Professor
Rutgers University
Pediatric Pharmacist
Cooperman Barnabas Medical Center
Piscataway, New Jersey

Jamie Miller, PharmD, BCPS, BCPPS, FPPA
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Jill A. Morgan, PharmD, BCPS, BCPPS, FNAP
Professor and Chair
University of Maryland School of Pharmacy
Baltimore, Maryland

Kimberly J. Novak, PharmD, BCPS, BCPPS, FPPA
Advanced Patient Care Pharmacist – Pulmonary Medicine
Nationwide Children's Hospital
Columbus, Ohio

E. Zachary Ramsey, PharmD, BCPPS
Clinical Pharmacy Specialist in Pediatric Cardiology
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Kathryn Rose, PharmD, BCPS, BCIDP, BCPPS
Division Director of Clinical Pharmacy
HCA/Health Trust
Adjunct Assistant Professor
University of Texas College of Pharmacy
Austin, Texas

Chasity M. Shelton, PharmD, FCCP, BCPS, BCPPS
Assistant Dean
Student Success and Associate Professor
Department of Clinical Pharmacy & Translational Science
The University of Tennessee Health Science Center
Memphis, Tennessee

Jennifer Thackray, PharmD, BCPS, BCPPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Lisa T. Thames, PharmD, BCPS
Assistant Director, Inpatient Pharmacy Services
UF Health Shands Hospital
Gainesville, Florida

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

  •          No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the CPE activity.


This online activity consists of a combined total of 9 learning modules. Pharmacists are eligible to receive a total of 27.5 hours of continuing education credit by completing all 9 modules within this professional certificate. 

Participants must participate in the entire activity and complete the evaluation and all required components to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts to claim credit and view your statement of credit within 60 days of completing the activity.

Important Note – ACPE 60 Day Deadline: 

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP profile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.